<a href="https://www.fiercebiotech.com/biotech/genentech-executes-another-round-layoffs-3-vps-axed" hreflang="en">Genentech executes another round of layoffs, with 3 VPs axed</a>
Genentech has announced layoffs affecting several vice presidents as part of a restructuring within its Research and Early Development group, aimed at aligning resources with core therapeutic areas. This follows previous job cuts and reflects the company's ongoing adjustments to maintain competitiveness in the biotech industry.
Genentech's recent layoffs, including high-level VPs, signify a strategic shift in their research focus, particularly the closure of physiological chemistry and infectious disease units. For someone tracking investment opportunities or strategic shifts in biotech, this indicates a potential realignment towards core therapeutic areas, which might signal where Genentech and Roche will prioritize future innovations and investments.